Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and v...
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
- Associated Therapies
- -
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2022-11-04
- Target Recruit Count
- 22
- Registration Number
- NCT02780609
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
- Conditions
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT02519842
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 942
- Registration Number
- NCT02106494
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HAL, Pheonix, Arizona, United States
🇺🇸Northern Indiana Research, South Bend, Indiana, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 13
- Registration Number
- NCT01874119
- Locations
- 🇺🇸
Saint Louis University Hospital, Saint Louis, Missouri, United States
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT01857232
- Locations
- 🇩🇰
Odense University Hospital, Odense, Denmark
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Lawrence Einhorn
- Target Recruit Count
- 65
- Registration Number
- NCT01736917
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Siteman Cancer Center, St. Louis, Missouri, United States
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 240
- Registration Number
- NCT01697579
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01490060
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Gynecologic Oncology Associates
- Target Recruit Count
- 20
- Registration Number
- NCT01432015
- Locations
- 🇺🇸
Gynecologic Oncology Associates, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.